Canada | NATO DIANA Energy & Power 2026
Whole-Blood Conversion Unit capable of converting A, B and AB-type whole blood into universal blood
NATO DIANA 2026 Cohort
Avivo Biomedical Inc. is developing a Whole-Blood Conversion Unit capable of transforming A, B, and AB-type whole blood into universal blood. This technology aims to eliminate the critical barrier of blood type matching in transfusions and organ transplants. Their innovation focuses on optimizing the existing blood supply by making it universally compatible.
Avivo's primary differentiator is its ability to eliminate blood type constraints for both transfusions and organ transplants, a significant departure from traditional medical practices. This allows for universal compatibility, reducing organ waste and ensuring that patients can receive life-saving interventions regardless of their specific blood type. The focus is on optimizing the existing blood supply rather than creating substitutes.
For defense, Avivo's technology offers a revolutionary leap in human resilience and battlefield medicine, significantly simplifying blood supply logistics in austere or mass casualty environments. The ability to convert any blood type into universal blood drastically reduces the logistical burden of maintaining diverse blood inventories. This directly enhances operational readiness and the survivability of personnel in critical situations, where timely and compatible blood is often a limiting factor.
While initial investment in the conversion units and associated processes may be significant, the long-term ROI for defense is substantial, including reduced waste of expired or mismatched blood products and improved patient outcomes. The logistical simplification and enhanced readiness could lead to considerable savings in supply chain management and personnel training. More importantly, it offers an invaluable return in saved lives and increased operational effectiveness.
Avivo Biomedical Inc. is currently in an advanced research and development phase, evidenced by their know-how agreement with Mayo Clinic for advancement of the technology. While not yet commercialized, this partnership indicates a TRL (Technology Readiness Level) likely in the 4-6 range, moving from laboratory validation towards system prototyping and demonstration in relevant environments. The technology is actively being developed for clinical application.
Avivo Biomedical Inc. is pioneering a Whole-Blood Conversion Unit that transforms A, B, and AB-type whole blood into universal blood. This innovation eliminates blood type matching barriers for transfusions and organ transplants, enabling medical professionals to prioritize patients by medical need, save more lives, and reduce organ waste. The technology significantly optimizes the existing blood supply and enhances logistical efficiency for critical medical interventions.